Frenelle Private Investor Briefing - NYC

by CONNECTpreneur Investor Network

Monday, October 5, 5:30 pm EDT

Long-acting injectable treatments offer an opportunity to improve access, adherence, and patient experience. Frenelle is applying its proprietary Faros™ drug-delivery technology to one of healthcare’s most significant unmet needs: Opioid Use Disorder.

​Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing featuring Frenelle PBC and FRN01, a 30-day subcutaneous buprenorphine injection designed to provide sustained OUD treatment with a more patient-friendly injection experience.

​Why Investors Are Taking Notice

​$1.2B+ Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, while long-acting treatment remains underpenetrated among patients receiving OUD treatment.

​Differentiated Approach — FRN01 is designed to address key barriers associated with existing long-acting products, including injection-site pain, cost, and access.

​Promising Preclinical Results — Recent PK and toxicology work demonstrated sustained drug levels over 30 days, low burst release, and a clean toxicology profile.

​Experienced Team + Mayo Clinic — Frenelle combines an experienced pharmaceutical development team with Mayo Clinic addiction medicine expertise.

​Minimum Check Size: $200K

​Event Details:

​Date: October 5

​Time: 5:30 - 7:30 pm ET

​Location: NYC, NY

​Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

​Request investor materials by contacting Skylar Rallison at srallison@opus8.com.